Clinical Trials
495 trialsPreliminary Assessment of [18F]BL40 in PET/CT Scans
British Columbia Cancer Agency
Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma
Centre Antoine Lacassagne
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
Dana-Farber Cancer Institute
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
University of Washington
SPiReL
Sunnybrook Health Sciences Centre
Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
City of Hope Medical Center
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
Mayo Clinic
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center
RICER
Hackensack Meridian Health
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
Calibr, a division of Scripps Research
INCA
University College, London
IT-TT as an Effective and Well-Tolerated Strategy for CNS Prop in High-Risk DLBCL: a Prospective Ph II Study
Zhejiang Cancer Hospital
Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma
The First Hospital of Jilin University
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
University of Chicago
Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma
The Lymphoma Academic Research Organisation
Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes
H. Lee Moffitt Cancer Center and Research Institute
EVAPOR
University Hospital, Tours
Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy
Institute of Hematology & Blood Diseases Hospital, China
Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies
H. Lee Moffitt Cancer Center and Research Institute
Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
LYMPHO-CLEAR
Centre Henri Becquerel
SIMILY
Institut Claudius Regaud
Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)
Massachusetts General Hospital
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant
M.D. Anderson Cancer Center
DA-EPOCH-R
Baylor College of Medicine
CHARTHER
IRCCS San Raffaele
LNH2007-3B
Hospices Civils de Lyon
FRAIL-06
Institut Bergonié
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
Universität des Saarlandes
BEB
Insel Gruppe AG, University Hospital Bern
Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement
International Extranodal Lymphoma Study Group (IELSG)
Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma
Northwestern University
Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance
Fox Chase Cancer Center
Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting
Vanderbilt-Ingram Cancer Center
Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
City of Hope Medical Center
Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood
M.D. Anderson Cancer Center
Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma
M.D. Anderson Cancer Center
Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study
Emory University
Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Off the Beaten Track" Liquid Biopsy
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Comparison of Whole-body MRI, Circulating DNA and PET-CT in Staging, Prognosis, and Treatment Response in Patients with Diffuse Large Cell B Lymphoma
Charles University, Czech Republic
Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
Mayo Clinic
ImbruVeRCHOP
Charite University, Berlin, Germany
Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma
Medical University of South Carolina
Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies
Vanderbilt-Ingram Cancer Center
Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea